Research and Markets: Cennapharm the Life Sciences Company is Trying to Bring New Drugs to the Market to Treat Irritable Bowel Syndrome.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c32374) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd report: Cennapharm Drug-Delivery Company Intelligence Report to their offering. Industry and commercial interest in drug delivery has been building steadily. The benefits to patients can be seen in improved compliance and medical outcomes, while the pharmaceutical industry is able to extend patent protection through novel delivery regimes and bring new therapies to the market that would, previously, have been impossible. These detailed company reports bring into focus the companies which driving growth and innovation in drug delivery. Over 140 leading players are examined with details for Company Overview, Key Personnel, Key Milestones, Products/Technologies, Research Strategy, Agreements, Financial Data and Associated Companies (if any) provided for each. Topics Covered: 1. Key Personnel 2. Company Overview 3. Key Milestones 4. Products/Technologies Summary Cennapharm is a life sciences company that applies a dual platform of patented technologies to develop and discover pharmaceutical formulas and delivery systems for combinations of highly active therapeutic compounds to different sites of action throughout the body. The company is working with large pharmaceutical partners to initially bring to market a pipeline of medications demonstrated to be effective in treating periodontal disease Periodontal Disease Definition Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where , urinary frequency and urgency, irritable bowel syndrome irritable bowel syndrome (IBS), condition characterized by frequently alternating constipation and diarrhea in the absence of any disease process. It is usually accompanied by abdominal pain, especially in the lower left quadrant, bloating, and flatulence. (IBS IBS Irritable bowel syndrome, see there ), oesophageal reflux Noun 1. oesophageal reflux - reflux of stomach contents into the esophagus esophageal reflux, gastroesophageal reflux reflux - an abnormal backward flow of body fluids disease (GORD) and osteoporosis. No current medications introduced to treat these diseases have a proven efficacy, according to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the company. Cennapharm's formulation technology makes possible a commercially viable medication and drug-delivery mechanism that acts within the body to regulate metabolic acidosis Metabolic Acidosis Definition Metabolic acidosis is a pH imbalance in which the body has accumulated too much acid and does not have enough bicarbonate to effectively neutralize the effects of the acid. ; a condition known for years to play a critical role in the development of osteoporosis, urinary frequency and urgency, and periodontal disease. Cennapharms technology enables researchers to precisely combine medications and chemicals compounds that were once considered incompatible to safely treat targeted diseased areas in the body. For more information visit http://www.researchandmarkets.com/reports/c32374 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion